Exopharm Limited (ASX:EX1) is a clinical-stage Australian biotechnology company developing extracellular vesicle (EV)/exosome-based therapeutics. Exopharm is developing engineered EVs for new precision medicines and naïve EV products for regenerative medicine, having been the first company in the world to test a proprietary naïve EV product in human clinical trials in early 2020. Exopharm’s core technology involves the isolation, purification, and engineering of EVs. The company’s LEAP Technology has been specifically developed to address the existing limitations in EV purification processes and gives Exopharm the opportunity to unlock the potential of EVs as new generation medical treatments.
Ticker:
EX1
Exchange:
ASX
Company Type:
Company Website:
Company HQ State:
Not Provided
Company HQ Country:
Australia
Year Founded:
2013
Main Therapeutic Focus:
Lead Product in Development:
Plexaris
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
3
Speaker
BIO DOUBLE HELIX SPONSORS
BIO HELIX SPONSORS
